Beam Therapeutics Inc. Stock Research

Market Summary

USD32.37+0.16

Market Closed

0.50%

BEAM Alerts

Big jump in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

BEAM Stock Price

BEAM RSI Chart

BEAM Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-7.62

Price/Sales (Trailing)

31.42

EV/EBITDA

-8.8

Price/Free Cashflow

-6.82

BEAM Price/Sales (Trailing)

BEAM Profitability

EBT Margin

-427.08%

Return on Equity

-39.41%

Return on Assets

-21.55%

Free Cashflow Yield

-14.67%

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

76.7M

Revenue Y/Y

187.1%

Revenue Q/Q

20.82%

BEAM Earnings

Earnings (TTM)

-316.3M

Earnings Y/Y

-39.36%

Earnings Q/Q

-151.53%

Price Action

52 Week Range

28.0473.27

(Low)(High)

Last 7 days

-6.3%

Last 30 days

6.0%

Last 90 days

-16.8%

Trailing 12 Months

-0.6%

BEAM Financial Health

Current Ratio

4.89

BEAM Investor Care

Shares Dilution (1Y)

6.71%

Diluted EPS (TTM)

-4.45

Peers (Alternatives to Beam Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	115.9B	26.2B	-9.16%	-12.25%	14.64	4.43	-0.48%	38.34%
GILD	96.2B	27.0B	-7.94%	24.63%	17.23	3.56	-1.56%	23.65%
MRNA	48.5B	15.1B	-3.43%	-7.04%	10.13	3.22	-33.37%	-67.32%
BIIB	43.1B	10.1B	3.69%	46.24%	13.77	4.27	-6.61%	115.98%
MID-CAP
NBIX	8.9B	1.6B	-11.20%	1.54%	138.97	5.56	32.38%	-10.36%
DNLI	4.1B	-	22.94%	24.01%	-11.06	37.77	122.90%	-29.67%
BEAM	2.4B	76.7M	5.96%	-0.58%	-7.62	31.42	41.73%	-32.75%
BBIO	2.2B	107.9M	-3.78%	107.70%	-4.55	20.44	54.84%	17.36%
SMALL-CAP
RCUS	1.6B	119.0M	22.46%	21.04%	-5.77	13.53	-69.61%	-584.39%
REPL	1.1B	10.0M	16.71%	38.03%	-6.34	110.4	215.65%	-47.65%
NVAX	622.2M	-	-4.25%	-84.68%	-0.54	0.31	72.89%	12.32%
FATE	503.7M	136.9M	-11.86%	-77.13%	-2.14	3.68	116.83%	-0.93%
SGMO	210.2M	241.0M	-21.74%	-64.41%	-1.65	0.87	113.96%	27.87%
VXRT	162.7M	697.0K	67.22%	-64.71%	-1.51	233.45	47.98%	-35.48%
IBIO	9.3M	-	-31.01%	-87.63%	-0.12	3.21	0.51%	-129.47%

Financials for Beam Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	25.9%	76,696,000	60,920,000	58,651,000	56,382,000	54,113,000
Operating Expenses	9.6%	437,878,000	399,399,000	404,930,000	368,225,000	328,587,000
S&GA Expenses	4.8%	92,048,000	87,805,000	82,896,000	76,855,000	66,196,000
R&D Expenses	11.0%	345,830,000	311,594,000	322,034,000	291,370,000	262,391,000
EBITDA	12.1%	-245,655,000	-279,483,000	-	-	-
EBITDA Margin	15.4%	-4.03	-4.77	-	-	-
Earnings Before Taxes	11.1%	-260,178,000	-292,744,000	-	-	-
EBT Margin	14.4%	-4.27	-4.99	-	-	-
Interest Expenses	-13.6%	325,000	376,000	424,000	474,000	521,000
Net Income	-9.4%	-316,334,000	-289,088,000	-315,446,000	-233,989,000	-238,292,000
Net Income Margin	11.8%	-4.75	-5.38	-4.51	-	-
Free Cahsflow	-166.9%	-26,424,000	39,489,000	122,999,000	148,208,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-0.7%	1,332	1,342	1,350	1,418	1,453
Current Assets	-0.9%	1,083	1,093	1,109	1,180	1,239
Cash Equivalents	11.5%	260	233	157	266	297
Net PPE	5.4%	122	116	111	106	94.00
Liabilities	-6.1%	571	608	636	618	624
Current Liabilities	-1.6%	220	224	239	212	219
Shareholder's Equity	3.8%	762	733	714	800	829
Retained Earnings	-4.9%	-1,153	-1,100	-1,000	-909	-837
Additional Paid-In Capital	6.9%	1,915	1,793	1,737	1,713	1,669
Accumulated Depreciation	15.3%	26.00	23.00	19.00	-	-
Shares Outstanding	4.4%	74.00	71.00	70.00	70.00	70.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-1457.4%	-305	23.00	94.00	171	191
Share Based Compensation	7.0%	90.00	84.00	77.00	68.00	57.00
Cashflow From Investing	122.0%	101	-461	-652	-539	-551
Cashflow From Financing	38.3%	154	112	101	420	559

Risks for BEAM

What is the probability of a big loss on BEAM?

66.5%

Probability that Beam Therapeutics stock will be more than 20% underwater in next one year

66.5%

Probability that Beam Therapeutics stock will be more than 30% underwater in next one year.

50.8%

Probability that Beam Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BEAM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Beam Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for BEAM

Cumulative Returns on BEAM

-7.0%

10-Year Cumulative Returns

10%

3-Year Cumulative Returns

What are the long-term rolling returns for BEAM?

FIve years rolling returns for Beam Therapeutics.

Annualized Returns

Which funds bought or sold BEAM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-23	Capital Impact Advisors, LLC	added	3.66	-89,570	385,812	0.47%
2023-05-22	UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO	new	-	1,832,000	1,832,000	0.70%
2023-05-22	AMERIPRISE FINANCIAL INC	sold off	-100	-287,000	-	-%
2023-05-18	INTERNATIONAL BIOTECHNOLOGY TRUST PLC	unchanged	-	-201,160	717,925	0.20%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-18.62	-786,000	1,381,000	-%
2023-05-18	JPMORGAN CHASE & CO	reduced	-2.6	-6,884,690	22,111,300	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-1,103	3,981	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	reduced	-34.12	-185,924	219,016	-%
2023-05-16	Ancora Advisors, LLC	unchanged	-	-469	1,531	-%
2023-05-16	CHILTON CAPITAL MANAGEMENT LLC	new	-	3,828	3,828	-%

Latest Funds Activity

Are funds buying BEAM calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own BEAM

No. of Funds

Beam Therapeutics News

Schedule 13G FIlings of Beam Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 17, 2023	temasek holdings (private) ltd	5.0%	3,644,573	SC 13G
Feb 14, 2023	farallon capital partners, l.p.	0.0%	0	SC 13G/A
Feb 10, 2023	temasek holdings (private) ltd	4.1%	2,878,297	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.90%	6,273,630	SC 13G/A
Feb 02, 2023	blackrock inc.	7.4%	5,238,280	SC 13G/A
Jul 14, 2022	farallon capital partners, l.p.	0.4%	276,948	SC 13G
Feb 14, 2022	arch venture fund ix, l.p.	8.6%	5,843,039	SC 13G/A
Feb 14, 2022	redmile group, llc	2.8%	1,885,850	SC 13G/A
Feb 14, 2022	temasek holdings (private) ltd	5.8%	3,959,212	SC 13G/A

BEAM Fair Value

Recent SEC filings of Beam Therapeutics

View All Filings

Date Filed	Form Type	Document
May 10, 2023	10-Q	Quarterly Report
May 10, 2023	424B5	Prospectus Filed
May 10, 2023	8-K	Current Report
May 10, 2023	8-K	Current Report
Apr 21, 2023	ARS	ARS
Apr 21, 2023	DEF 14A	DEF 14A
Apr 21, 2023	DEFA14A	DEFA14A
Apr 19, 2023	4/A	Insider Trading
Apr 05, 2023	4	Insider Trading
Apr 05, 2023	4	Insider Trading

Latest Insider Trading transactions for BEAM

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-04-04	Simon Amy	sold	-346,115	29.6993	-11,654	chief medical officer
2023-04-04	Evans John M.	sold	-188,904	29.0935	-6,493	ceo
2023-04-04	Bellon Christine	sold	-33,777	29.0931	-1,161	chief legal officer
2023-04-04	Burrell Terry-Ann	sold	-63,597	29.0931	-2,186	chief financial officer
2023-04-04	Ciaramella Giuseppe	sold	-51,028	29.0929	-1,754	president & cso
2023-04-03	Simon Amy	sold	-134,728	30.31	-4,445	chief medical officer
2023-04-03	Ciaramella Giuseppe	sold	-58,134	30.31	-1,918	president & cso
2023-04-03	Burrell Terry-Ann	sold	-74,380	30.31	-2,454	chief financial officer
2023-04-03	Bellon Christine	sold	-28,218	30.31	-931	chief legal officer
2023-04-03	Evans John M.	sold	-156,430	30.31	-5,161	ceo

About Beam Therapeutics

John Evans

www.beamtx.com

340

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Income Statement

2023-03-31

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
License and collaboration revenue	$ 24,208	$ 8,432
Revenue, Product and Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 99,646	$ 65,410
General and administrative	23,490	19,247
Total operating expenses	123,136	84,657
Loss from operations	(98,928)	(76,225)
Other income (expense):
Change in fair value of derivative liabilities	5,600	13,600
Change in fair value of non-controlling equity investments	(12,797)	(7,685)
Change in fair value of contingent consideration liabilities	(296)	452
Interest and other income (expense), net	9,961	644
Total other income (expense)	2,468	7,011
Net loss	(96,460)	(69,214)
Unrealized gain (loss) on marketable securities	1,665	(2,659)
Comprehensive loss	$ (94,795)	$ (71,873)
Net loss per common share, basic	$ (1.33)	$ (1.01)
Net loss per common share, diluted	$ (1.33)	$ (1.01)
Weighted - average common shares outstanding, basic	72,273,829	68,703,864
Weighted - average common shares outstanding, diluted	72,273,829	68,703,864

BEAM Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 249,771	$ 232,767
Marketable securities	809,700	845,367
Prepaid expenses and other current assets	23,560	14,762
Total current assets	1,083,031	1,092,896
Property and equipment, net	121,822	115,620
Restricted cash	9,802	12,754
Operating lease right-of-use assets	116,159	118,513
Other assets	1,538	1,931
Total assets	1,332,352	1,341,714
Current liabilities:
Accounts payable	14,063	9,029
Accrued expenses and other current liabilities	37,847	48,059
Derivative liabilities	12,700	18,300
Current portion of deferred revenue	142,737	135,974
Current portion of lease liability	11,157	10,380
Current portion of equipment financing liability	1,421	1,853
Total current liabilities	219,925	223,595
Long-term lease liability	165,298	168,625
Long-term equipment financing liability	983	1,154
Contingent consideration liabilities	12,759	12,463
Long-term portion of deferred revenue	171,708	202,179
Other liabilities	173	224
Total liabilities	570,846	608,240
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2023 and December 31, 2022 , respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 74,435,392 and 71,277,339 issued and outstanding at March 31,2023 and December 31, 2022 respectively	744	712
Additional paid-in capital	1,915,349	1,792,554
Accumulated other comprehensive (loss) income	(765)	(2,430)
Accumulated deficit	(1,153,822)	(1,057,362)
Total stockholders' equity	761,506	733,474
Total liabilities and stockholders' equity	$ 1,332,352	$ 1,341,714